Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children - Vapotherm (NYSE:VAPO)

Vapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of

Related Keywords

Brighton ,Brighton And Hove ,United Kingdom ,United States ,Sussex ,East Sussex ,Exeter ,Devon ,New Hampshire ,America ,Paul Seddon ,Hector Rojas Anaya ,Allergy Foundation Of America ,European Respiratory Society International Congress ,Vapotherm Inc ,Sussex Clinical Trial Unit At University Hospitals ,Exchange Commission ,Emergency Department ,Joe Army ,Sussex Clinical Trial Unit ,University Hospitals ,Jessica Whittle ,Chief Medical Officer ,Allergy Foundation ,Precision Flow ,Investor Relations ,